CD8A and neoplasm: Critically, CD47 × PD‐L1 BisAb treatment resulted in significantly greater IFNγ‐producing CD8+ T cells in the tumor and spleen (Figure 4f and Supplementary figure 5e) than anti‐PD‐L1 alone.